A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
GlaxoSmithKline
845 participants
Sep 30, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ris-Rez will be administered
Cisplatin will be administered
Carboplatin will be administered
Atezolizumab will be administered
Pembrolizumab will be administered
Durvalumab will be administered
Cetuximab will be administered
Bevacizumab will be administered
Tarlatamab will be administered
Dostarlimab will be administered
Locations(67)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06551142